RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM
Status:
Withdrawn
Trial end date:
2021-04-13
Target enrollment:
Participant gender:
Summary
The primary aim of this study is to test whether Doxycycline can benefit patients with severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections by inhibiting the
replication of the virus while at the same time blocking the development of cytokine storms
or inhibiting cytokine-associated coagulopathy respectively. The investigators hypothesize
that Doxycycline will will improve survival and reduce morbidity in SARS-CoV-2 infected
patients.
A secondary aim is to identify genetic variants that predict either an unusually mild disease
or an unusually severe disease - knowledge that can be used to design new and precise
medications and to be able to predict patients who might get into early trouble and to
therefore hospitalize them.